News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
86 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17535)
Month
January (2883)
February (2030)
March (1769)
April (2200)
May (2664)
June (3162)
July (3087)
August (3801)
September (4260)
October (5136)
November (4629)
December (3503)
Day
1 (92)
2 (55)
3 (1)
4 (4)
5 (65)
6 (116)
7 (86)
8 (101)
9 (46)
10 (4)
11 (5)
12 (90)
13 (97)
14 (81)
15 (116)
16 (43)
17 (1)
18 (12)
19 (98)
20 (90)
21 (83)
22 (111)
23 (47)
26 (66)
27 (70)
28 (93)
29 (55)
30 (39)
31 (2)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
26
27
28
29
30
31
Business
Roivant Licenses Diabetes Drug From Ligand Pharma
Ligand Pharmaceuticals is licensing LGD-6972, a glucagon receptor antagonist (GRA), to Roivant Sciences for $20 million.
March 7, 2018
·
3 min read
·
Mark Terry
FDA
FDA Greenlights New Treatment for Multi-Drug Resistant HIV-1
The U.S. Food and Drug Administration has approved Trogarzo (ibalizumab), the first HIV-1 inhibitor for patients with multi-drug resistant HIV-1.
March 7, 2018
·
2 min read
·
Alex Keown
Drug Development
Esperion’s Cholesterol Drug Positive in PhIII Trial
Esperion announced that its bempedoic acid for lowering LDL-C cholesterol had positive results in a Phase III clinical trial.
March 7, 2018
·
3 min read
·
Mark Terry
Business
Moderna’s Vaccines Boss Leaves Company
Giuseppe Ciaramella, formerly chief scientific officer of Moderna Therapeutics’ Valera unit, has left for an unidentified stealth-mode biotech startup.
March 7, 2018
·
3 min read
·
Mark Terry
Drug Development
Seattle Genetics Commences Dosing in Early-Stage Multiple Myeloma Trial
Seattle Genetics dosed its first patient with an early-stage treatment for patients with relapsed or refractory multiple myeloma (MM).
March 7, 2018
·
2 min read
·
Alex Keown
Biotech Bay
CDC Report Indicates Opioid Crisis in America is Worsening
The CDC report shows opioid-related emergency room visits spiked 30 percent over a period of one year.
March 7, 2018
·
2 min read
·
Alex Keown
Business
Arkansas Urology First Urology Practice in Arkansas to Acquire Novel ExactVu; Micro-Ultrasound System for Prostate Imaging and Biopsy
New state-of-the-art micro-ultrasound system allows Arkansas Urology’s patients to benefit from the latest imaging technologies
March 7, 2018
·
4 min read
BioForest
New Prevencio Study Using AI Demonstrates Simple Blood Test Accurately Diagnoses Aortic Stenosis
Prevencio Inc. announces its HARTTM AS multi-protein, artificial intelligence (AI)-driven test, which data indicates accurately diagnoses Aortic Stenosis (AS)—a condition with a 50 percent death rate when left untreated.
March 7, 2018
·
3 min read
FDA
Panther Orthopedics, Inc. Receives FDA 510(k) Clearance for the PUMA System(TM) - An Orthopedic Flexible Fixation Device
The PUMA SystemTM represents a revolutionary advancement in the treatment of orthopedic injuries by allowing normal anatomical motion of the joint while maintaining continuous compression.
March 7, 2018
·
1 min read
BioMidwest
Hill-Rom Raises Quarterly Dividend
The board of directors declared an 11 percent increase in the company’s quarterly dividend rate.
March 7, 2018
·
1 min read
1 of 9
Next